J EXP MED 润色咨询

JOURNAL OF EXPERIMENTAL MEDICINE

出版年份:1896 年文章数:4592 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.6% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2024-01-30 solar93 来自广东省

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:免疫
    经验分享:建议免疫方向的文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2022-08-09 slientwo

    JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!

    3

    展开3条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2021-06-21 1784370827m

    审稿速度:1.0
    偏重的研究方向:免疫
    经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32

    5

    展开5条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2022-03-08 雪花莹

    投稿命中率:50.0
    偏重的研究方向:免疫
    经验分享:这是时间点,坐等修回意见
    Under External Review 2022-02-22
    Initial Manuscript Assessment Started
    Initial QC Complete 2022-02-10
    Initial QC Started 2022-02-09
    Author Approved Converted Files 2022-02-09
    Preliminary Manuscript Data Submitted 2022-02-09

    2

    展开2条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2022-04-16 1481188cm09(暂无昵称)

    审稿速度:1.0 | 投稿命中率:25.0
    偏重的研究方向:免疫
    经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2021-12-28 rayms

    ORCIDID是什么?怎么注册?

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2016-12-11 无敌的细胞

    审稿速度:2.0 | 投稿命中率:5.0
    经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2020-10-09 疯狂的丫头0731

    审稿速度:1.0 | 投稿命中率:25.0
    经验分享:一审一个月 给大家个参考

    1

    展开1条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-09-08 cecily1979

    11.99185****0357暂无昵称 2017-06-15 发表::
    SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--
    185****0357暂无昵称 2017-06-15 08:12:00 发表:
    JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--

    185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2184830, encodeId=fa0d21848309b, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:建议免疫方向的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=bTTYicUnlgLFUmvQgjuTiaQw&s=100&t=1555903394, createdBy=f7285276004, createdName=solar93, createdTime=Tue Jan 30 14:09:37 CST 2024, time=2024-01-30, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1237469, encodeId=5aec123e46969, content=JEM, EMBO J, JCI, G&D都是我的梦刊,我都想要!, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a2211714800, createdName=slientwo, createdTime=Tue Aug 09 00:21:05 CST 2022, time=2022-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=975312, encodeId=bdf19e53129f, content=审稿速度:1.0<br>偏重的研究方向:免疫<br>经验分享:审稿都是免疫学大牛,很友好、提问相当专业。文章大修了3个figure,附时间点: Preliminary Manuscript Data Submitted 2021-01-02 22:40:02 Under External Review 2021-01-14 17:08:05 Decision Sent to Author 2021-02-16 16:07:39 Revision Received 2021-05-05 22:26:29 Decision Sent to Author 2021-06-08 16:45:18 Manuscript Sent to Production 2021-06-17 16:08:32, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=122, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7434787988, createdName=1784370827m, createdTime=Mon Jun 21 07:54:02 CST 2021, time=2021-06-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1200696, encodeId=9ad51200696bd, content=投稿命中率:50.0<br>偏重的研究方向:免疫<br>经验分享:这是时间点,坐等修回意见<br>Under External Review 2022-02-22 <br>Initial Manuscript Assessment Started <br>Initial QC Complete 2022-02-10<br>Initial QC Started 2022-02-09 <br>Author Approved Converted Files 2022-02-09 <br>Preliminary Manuscript Data Submitted 2022-02-09 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=78, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/19/33743bc2d24e69358e6f25bd90b7d57b.jpg, createdBy=82831648405, createdName=雪花莹, createdTime=Tue Mar 08 22:06:55 CST 2022, time=2022-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1211741, encodeId=60f01211e4122, content=审稿速度:1.0 | 投稿命中率:25.0<br>偏重的研究方向:免疫<br>经验分享:1月送审,2个审稿人,意见都是比较positive 花了3个月补实验,然后过了1月接收,最后过了一个半月正式online.需要提供WB的原始数据, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ebc45266052, createdName=1481188cm09(暂无昵称), createdTime=Sat Apr 16 21:31:16 CST 2022, time=2022-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093116, encodeId=89901093116f8, content=ORCIDID是什么?怎么注册?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=71, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/6252e946e5ef413b86dc0f7d1f73b6db/9a7e8c88a38e487b8da4968a67bbd261.png, createdBy=b9f692910, createdName=rayms, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=530451, encodeId=95fc530451a1, content=审稿速度:2.0 | 投稿命中率:5.0<br>经验分享:近年来也开始接收除免疫以外的研究型论文。Nature medicine被拒,直接转投JEM。3月投稿,中间修回一次,11月底接收。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=524, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b20a1993485, createdName=无敌的细胞, createdTime=Sun Dec 11 16:28:00 CST 2016, time=2016-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=890899, encodeId=771289089948, content=审稿速度:1.0 | 投稿命中率:25.0<br>经验分享:一审一个月 给大家个参考, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=2, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76281996777, createdName=疯狂的丫头0731, createdTime=Fri Oct 09 23:10:12 CST 2020, time=2020-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546655, encodeId=b05454665562, content=11.99<span class="quote">185****0357暂无昵称 2017-06-15 发表::<br>SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span><span class="quote">185****0357暂无昵称 2017-06-15 08:12:00 发表:<br>JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--</span>, beContent=185****0357暂无昵称 2017-06-15 发表:: SCI(2015):11.24 SCI(2014):12.515 JEM的IF一路走低.比NC都低了 杂志社的办刊思路不对啊--过于集中免疫领域.但又没有那些大集团的子刊更具有吸引力 这么下去.尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊--, objectType=tool_impact_factor, channel=null, level=null, likeNumber=457, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIm8tJomt9YO8TUibdtDu6OMicjNzqpbYX2aicMicv2skvVkqkW2EKdZ9WnHsUUkCw1e3IrBx3nvaDa1Q/0, createdBy=04181926623, createdName=cecily1979, createdTime=Fri Sep 08 00:00:00 CST 2017, time=2017-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537920, encodeId=7b2a53e92034, content=JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=395, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e2a62075382, createdName=1851f102e3m, createdTime=Thu Jun 15 08:12:00 CST 2017, time=2017-06-15, status=1, ipAttribution=)]
    2017-06-15 1851f102e3m

    JEM的IF一路走低,比NC都低了 杂志社的办刊思路不对啊……过于集中免疫领域,但又没有那些大集团的子刊更具有吸引力 这么下去,尾随同一出版社的另一老牌杂志JCB跌下十分也不是不可能啊……

    0

共28条页码: 1/3页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分